vTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of its GLP-1 Receptor Agonist at 53rd Annual Meet...
September 07 2017 - 7:00AM
Business Wire
vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that
additional analysis from a Phase 2 clinical study of TTP273, an
investigational, oral small molecule GLP-1 receptor (GLP-1R)
agonist for the treatment of type 2 diabetes will be presented at
the 53rd Annual Meeting of the European Association for the Study
of Diabetes (EASD) held in Lisbon, Portugal, September 11 – 15,
2017.
Details of the presentation are listed below:
Presentation Title: “Beyond topline results for the oral
(non-peptide) GLP-1R agonist TTP273 in type 2 diabetes: How much
and when?”Session: OP 19 Novel therapies: Future
OpportunitiesPresentation Number: Oral Presentation #
112Date and Time: Wednesday, September 13, 2017, 2:30 –
4:00pm WESTLocation: International Fair of Lisbon, Roma
Hall
About TTP273
TTP273 is an oral small molecule that works by activating the
GLP-1 receptor. Activation of the GLP-1 receptor leads to the
enhancement of insulin secretion and suppression of glucagon
production and decreased food intake. There are currently several
marketed injectable GLP-1 therapies. These agents have demonstrated
notable glucose lowering in addition to weight loss; however, their
widespread use may be hindered by the route of administration
(injection) and by the high incidence of gastrointestinal side
effects (nausea and vomiting).
About Type 2 Diabetes
Type 2 diabetes is a result of the body’s inability to use
insulin properly to control sugar in the bloodstream. Type 2
diabetes represents up to 95% of diabetes patients, imposing a
growing burden on healthcare systems globally. Diabetes remains the
7th leading cause of death in the United States, costing the
healthcare system $245 billion annually. According to the American
Diabetes Association, there are 29.1 million Americans, or 9.3% of
the population, living with diabetes.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and type 2
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These forward-looking
statements reflect our views with respect to future events as of
the date of this release and are based on assumptions and subject
to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These
forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law,
we undertake no obligation to update or review publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise after the date of this release. We
anticipate that subsequent events and developments will cause our
views to change. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, merger, dispositions,
joint ventures or investments we may undertake. We qualify all of
our forward-looking statements by these cautionary statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170907005507/en/
Investors:vTv Therapeutics Inc.Michael Gibralter,
646-378-2938IR@vtvtherapeutics.comorMedia:Pure Communications
Inc.Christie Teller, 817-907-3619cteller@w2ogroup.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2023 to Apr 2024